Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study.

Gilad Sherman,Gabriella S Lamb,Tanvi S Sharma,Elizabeth C Lloyd,Jerod Nagel, Nada N Dandam,Carlos R Oliveira, Hassan S Sheikha,Brenda I Anosike, Philip Lee,Surabhi B Vora, Karisma Patel,Paul K Sue,Beenish Rubbab,April M Yarbrough,Lakshmi Ganapathi,Mari M Nakamura

Journal of the Pediatric Infectious Diseases Society（2023）

引用 2|浏览4

暂无评分

摘要

Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.

查看译文

关键词

COVID-19,SARS-CoV-2,bamlanivimab and etesevimab,casirivimab and imdevimab,monoclonal antibodies,pediatric

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要